Safety and efficacy of the combination treatment BRAFi +/- MEKi with anti-PD1 agents (pembrolizumab and nivolumab) in subjects with metastatic melanoma: A retrospective study

Trial Profile

Safety and efficacy of the combination treatment BRAFi +/- MEKi with anti-PD1 agents (pembrolizumab and nivolumab) in subjects with metastatic melanoma: A retrospective study

Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Aug 2016

At a glance

  • Drugs Mitogen-activated protein kinase kinase inhibitors (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary) ; Proto oncogene protein b raf inhibitors (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 05 Aug 2016 New trial record
    • 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top